Johnson & Johnson: The Dividend King Is Back
Johnson & Johnson is regaining momentum with strong growth in its Innovative Medicine and MedTech segments, driven by new products and strategic acquisitions. The company's robust financials, inclu...
Johnson & Johnson: Don't Bet Against Double Compounding
JNJ bulls often praise its dividends - rightfully. However, the above-average yield and remarkable dividend record understate the attractiveness. Investors should focus on total shareholder returns...
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
Eli Lilly's weight loss drugs are pushing the company's market cap toward $1 trillion. Johnson & Johnson is the global leader in drug sales, but its market cap is under $400 billion.
Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $161.43, denoting a +0.79% change from the preceding trading day.
Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion
The FDA has approved Rybrevant plus Lazcluze in the U.S. for the treatment of patients with non-small cell lung cancer.
Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025
24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.
J&J to disclose support for $6.5 billion talc settlement
Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products ca...
J&J has enough support from claimants for $6.5 billion talc settlement: report
Johnson & Johnson is reportedly nearing enough support to finalize a $6.5 billion settlement for lawsuits related to cancer cases linked to its baby powder and other talc products.
J&J's (JNJ) DePuy Synthes' TriLEAP System to Aid Ankle Surgery
Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.
2 Healthcare Stocks to Buy Hand Over Fist in August
Eli Lilly is a leader in diabetes and obesity care, but it's also making progress elsewhere. Johnson & Johnson has a robust underlying business, and a rare and ongoing dividend streak.
3 Defensive Stocks Weathering the Market Storm
In a week where fear, uncertainty, and widespread selling swept the market, three stocks stood out for their resilience: Johnson & Johnson NYSE: JNJ, Coca-Cola NYSE: KO, and Procter & Gamble NYSE: PG.
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the pandemic,...
Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?
Johnson & Johnson is attempting to resolve talc lawsuits through bankruptcy for a third time. This time around, it's letting claimants vote on its proposed settlement.
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment ...
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson's comprehensive PAH portfolio has the potential to cover all guideline-re...
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
Related Companies